Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00275704 · ClinicalTrials.gov registry record · Phase 2

Flaxseed for the Treatment of Hot Flashes

A Phase 2 study, sponsored by Mayo Clinic.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT00275704: Completed Phase 2 study, sponsored by Mayo Clinic.

NCT00275704 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00275704, a Phase 2 study, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

Flaxseed, a phytoestrogen, is a natural food supplement rich in plant ligands, which have a very weak estrogen effect. In this study, flaxseed is being evaluated in regard to its capacity to safely and effectively treat hot flashes. Specifically, this study seeks to determine if flaxseed will lower the number and severity of hot flashes and if women experience any side effects from taking flaxseed for this purpose.

Interventions

  • DRUG Flaxseed

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2005-05
Phase Phase 2
Mayo Clinic

2,844 total trials

What the finished NCT00275704 record still lists

NCT00275704 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 1 intervention - of which Flaxseed is the first listed.

NCT00275704 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00275704 about?

NCT00275704 is a clinical study titled "Flaxseed for the Treatment of Hot Flashes". Flaxseed, a phytoestrogen, is a natural food supplement rich in plant ligands, which have a very weak estrogen effect. In this study, flaxseed is being evaluated in regard to its capacity to safely and effectively treat hot flashes. Specifically, this study seeks to determine if flaxseed will lower ...

What is the current status of trial NCT00275704?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-05.

What interventions are being tested in trial NCT00275704?

The interventions under investigation include: Flaxseed (DRUG).

Who is sponsoring clinical trial NCT00275704?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00275704's enrollment target sits among peer trials

30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00275704, the US trial registry maintained by the National Library of Medicine. NCT00275704 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.